v3.25.2
Acquisition of Pionyr - Additional Information (Details) - IKENA ONCOLOGY INC - Pionyr Immunotherapeutics, Inc
$ in Millions
Aug. 04, 2023
USD ($)
shares
Business Acquisition [Line Items]  
Business acquisition, contingent value right received for each share 1
Percentage of net proceeds from potential monetization of legacy programs receivable 50.00%
Business acquisition, transaction cost | $ $ 1.3
Common Stock  
Business Acquisition [Line Items]  
Business acquisition, shares issued 150,054
Non-voting Common Stock  
Business Acquisition [Line Items]  
Business acquisition, shares issued 12,760
Series A Preferred Stock  
Business Acquisition [Line Items]  
Business acquisition, shares issued 4,153,439